

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, ...
Q2 2026
Aug 6, 2026
Q1 2026
May 11, 2026
FY 2025
Mar 10, 2026
Q4 2025
Mar 10, 2026
Q3 2025
Nov 10, 2025